These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 12647444)

  • 41. Amisulpride versus olanzapine in the treatment of schizophrenia in Indian patients: randomized controlled trial.
    Bhowmick S; Hazra A; Ghosh M
    Aust N Z J Psychiatry; 2010 Mar; 44(3):237-42. PubMed ID: 20050717
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Serotonin and dopamine antagonism in obsessive-compulsive disorder: effect of atypical antipsychotic drugs.
    Ramasubbu R; Ravindran A; Lapierre Y
    Pharmacopsychiatry; 2000 Nov; 33(6):236-8. PubMed ID: 11147933
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Long-term therapy with intuition].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():87. PubMed ID: 14579492
    [No Abstract]   [Full Text] [Related]  

  • 44. [Augmentation of selective serotonin reuptake inhibitors (SSRI) with atypical antipsychotics in the treatment of depression].
    Weimer E; Braus DF; Cavus I; Thome J
    Fortschr Neurol Psychiatr; 2002 Apr; 70(4):210-7. PubMed ID: 11948436
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Switching clozapine responders to olanzapine.
    Littrell KH; Johnson CG; Hilligoss NM; Peabody CD; Littrell SH
    J Clin Psychiatry; 2000 Dec; 61(12):912-5. PubMed ID: 11206595
    [TBL] [Abstract][Full Text] [Related]  

  • 46. High-dose olanzapine for treatment-refractory schizophrenia.
    Lerner V
    Clin Neuropharmacol; 2003; 26(2):58-61. PubMed ID: 12671523
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Prospective observational study of outpatients with schizophrenia in Poland: preliminary 6 month efficacy and tolerability results].
    Meder J; Debowska G; Lis J; Araszkiewicz A; Sierosławska K; Kolesaric A; Treuer T
    Psychiatr Pol; 2004; 38(3):469-84. PubMed ID: 15199656
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The PRIME North America randomized double-blind clinical trial of olanzapine versus placebo in patients at risk of being prodromally symptomatic for psychosis. II. Baseline characteristics of the "prodromal" sample.
    Miller TJ; Zipursky RB; Perkins D; Addington J; Woods SW; Hawkins KA; Hoffman R; Preda A; Epstein I; Addington D; Lindborg S; Marquez E; Tohen M; Breier A; McGlashan TH
    Schizophr Res; 2003 May; 61(1):19-30. PubMed ID: 12648732
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Fast control of manic or mixed episodes. Atypical neuroleptics for bipolar patients].
    MMW Fortschr Med; 2003 May; 145 Suppl 2():86-7. PubMed ID: 14579491
    [No Abstract]   [Full Text] [Related]  

  • 50. Olanzapine for schizophrenia refractory to typical and atypical antipsychotics: an open-label, prospective trial.
    Lindenmayer JP; Volavka J; Lieberman J; Sheitman B; Citrome L; Chakos M; Czobor P; Parker B; Iskander A
    J Clin Psychopharmacol; 2001 Aug; 21(4):448-53. PubMed ID: 11476131
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Olanzapine augmentation of clozapine.
    Gupta S; Sonnenberg SJ; Frank B
    Ann Clin Psychiatry; 1998 Sep; 10(3):113-5. PubMed ID: 9781474
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Olanzapine orally disintegrating tablets in the treatment of acutely ill non-compliant patients with schizophrenia.
    Kinon BJ; Hill AL; Liu H; Kollack-Walker S
    Int J Neuropsychopharmacol; 2003 Jun; 6(2):97-102. PubMed ID: 12890301
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Olanzapine: safe during clozapine-induced agranulocytosis.
    Oyewumi LK; Al-Semaan Y
    J Clin Psychopharmacol; 2000 Apr; 20(2):279-81. PubMed ID: 10770478
    [No Abstract]   [Full Text] [Related]  

  • 54. Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.
    Tollefson GD; Birkett MA; Kiesler GM; Wood AJ;
    Biol Psychiatry; 2001 Jan; 49(1):52-63. PubMed ID: 11163780
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Switching outpatients with schizophrenia and related disorders on long-acting injectable antipsychotics to olanzapine: an open-label naturalistic pilot study.
    Labelle A; Bourget D; Boulay LJ; Ellis J; Tessier P
    J Clin Psychopharmacol; 2002 Dec; 22(6):545-53. PubMed ID: 12454553
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Effect of olanzapine treatment on cognitive functions in patients with schizophrenia].
    Radziwiłłowicz P; Radziwiłłowicz W; Lis J
    Psychiatr Pol; 2002; 36(6):967-87. PubMed ID: 12725025
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Olanzapine for schizophrenia.
    Med Lett Drugs Ther; 1997 Jan; 39(992):5-6. PubMed ID: 9008682
    [No Abstract]   [Full Text] [Related]  

  • 58. Olanzapine for violent schizophrenia and Klinefelter syndrome.
    Dervaux A; Artiges E
    Am J Psychiatry; 2002 Mar; 159(3):493-4. PubMed ID: 11870023
    [No Abstract]   [Full Text] [Related]  

  • 59. Olanzapine-induced manic-like syndrome.
    Lindenmayer JP; Klebanov R
    J Clin Psychiatry; 1998 Jun; 59(6):318-9. PubMed ID: 9671347
    [No Abstract]   [Full Text] [Related]  

  • 60. Olanzapine and negative and positive symptoms.
    Rifkin A
    Am J Psychiatry; 2001 May; 158(5):825. PubMed ID: 11329430
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.